Myriad Genetics MYGN Weighted Average Exercise Price of Outstanding Options
Weighted Average Exercise Price of Outstanding Options at other companies
Other financials
Where this comes from
Reported directly by Myriad Genetics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.
The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Myriad Genetics's weighted average exercise price of outstanding options.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Myriad Genetics's weighted average exercise price of outstanding options?
- Myriad Genetics (MYGN) reported weighted average exercise price of outstanding options of $13.38 in Q1 2026.
- How has Myriad Genetics's weighted average exercise price of outstanding options changed year-over-year?
- Myriad Genetics's weighted average exercise price of outstanding options decreased by 0.0% year-over-year, from $13.38 to $13.38.
- What is the long-term trend for Myriad Genetics's weighted average exercise price of outstanding options?
- Over 5 years (2020 to 2025), Myriad Genetics's weighted average exercise price of outstanding options has grown at a -10.5% compound annual growth rate (CAGR), from $23.24 to $13.38.
- What does weighted average exercise price of outstanding options mean?
- This metric calculates the average price at which holders of outstanding stock options can purchase company shares. It provides context on the 'in-the-money' status of employee compensation packages. When compared to the current market price, it helps assess the alignment between employee incentives and shareholder value.